Aster Capital Management DIFC Ltd Makes New Investment in iShares Biotechnology ETF $IBB

Group 1: Investment Activity - Aster Capital Management DIFC Ltd acquired 13,210 shares of iShares Biotechnology ETF valued at approximately $1,907,000, making it the 14th largest position in their portfolio [2] - Citigroup Inc. increased its holdings in iShares Biotechnology ETF by 27.0%, now owning 4,073,967 shares valued at $515,398,000 after purchasing an additional 865,823 shares [3] - JPMorgan Chase & Co. boosted its position by 74.2%, now holding 833,196 shares valued at $105,408,000 after buying 355,000 shares [3] - Employees Retirement System of Texas acquired a new stake valued at $25,049,000 [3] - Millennium Management LLC increased its stake by 140.8%, now owning 41,676 shares valued at $5,330,000 after buying 143,893 shares [3] - Florin Court Capital LLP bought a new stake worth $11,116,000 [3] - Institutional investors and hedge funds currently own 62.45% of the stock [3] Group 2: Stock Performance - iShares Biotechnology ETF shares opened at $173.88, with a 50-day simple moving average of $172.77 and a 200-day simple moving average of $159.84 [4] - The ETF has a 12-month low of $107.43 and a 12-month high of $179.64 [4] Group 3: Dividend Information - iShares Biotechnology ETF announced a quarterly dividend of $0.1831, an increase from the previous dividend of $0.08 [5][6] - The annualized dividend is $0.73, resulting in a dividend yield of 0.4% [5][6] Group 4: Fund Overview - iShares Nasdaq Biotechnology ETF seeks investment results that correspond to the price and yield performance of the NASDAQ Biotechnology Index, which includes securities of NASDAQ listed companies in biotechnology or pharmaceuticals [7]